TCA
JANX icon

Troluce Capital Advisors’s Janux Therapeutics JANX Stock Holding History

Troluce Capital Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,297
Closed -$872K – 39
2025
Q1 		$872K Hold
32,297
– – 0.26% 27
2024
Q4 		$1.73M Buy
+32,297
New +$1.71M 0.06% 29

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Troluce Capital Advisors's JANX Position: Q2 2025 in Review

Troluce Capital Advisors sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 32,297 shares — an estimated $872K sold.

Troluce Capital Advisors first reported a position in JANX in Q4 2024 and held it in 2 quarters. The position peaked at $1.73M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

  • Troluce Capital Advisors reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Troluce Capital Advisors sold 32,297 Janux Therapeutics shares in Q2 2025, an estimated $872K.
  • Troluce Capital Advisors first reported a position in Janux Therapeutics in Q4 2024 and held it in 2 quarters.
  • Troluce Capital Advisors's Janux Therapeutics position peaked at $1.73M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Troluce Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.